$6.55
2.82% yesterday
Nasdaq, Jun 27, 10:15 pm CET
ISIN
CA60255C1095
Symbol
MNMD
Sector
Industry

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock News

Positive
Proactive Investors
10 days ago
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration.   Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, ...
Neutral
Business Wire
19 days ago
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Compan...
Positive
The Motley Fool
24 days ago
Mind Medicine (MNMD 2.81%), a healthcare company that's looking to develop treatments based on psychedelic compounds, was something of a sleeper stock in May. Several positive developments pushed the highly specialized enterprise's share price higher, to the point where it closed the month up almost 14% in price.
Neutral
Business Wire
about one month ago
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies Global Healthcare Conference Format: Pres...
Neutral
Business Wire
about one month ago
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's exec...
Positive
The Motley Fool
about one month ago
Investors had a good mind to plow money into Mind Medicine (MNMD 8.13%) stock on Tuesday. Shares of the psychedelic-focused biotech, which also goes by the name of MindMed, provided a nice high by rising more than 8% in price on a legislative development.
Neutral
Business Wire
about one month ago
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 53,350 common shares of the Compan...
Neutral
Business Wire
about 2 months ago
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at the 2025 RBC Capital Markets Global Healthcare Conference: 2025 RBC Capital Markets Global Healthcare...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today